Pegvisomant is a successful drug (marketed by Pfizer and prescribed for acromegaly) which acts as a competitive inhibitor/antagonist of endogenous hGH binding to the hGHR and normalizes serum IGF1 in >90% of the patients in clinical trials. Here, IGF1 is linked to acromegaly.